Which questionnaires should we use to evaluate quality of life in patients with chronic graft-vs-host disease?

**Aim** To investigate the ability of two standard quality of life (QOL) questionnaires – The Short Form (36-item) Health Survey (SF-36) and The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ C30) to evaluate QOL in patients with chronic graft-vs-host disease (cGVHD) graded according to National Institutes of Health (NIH) consensus criteria.

**Methods** In this cross-sectional study, QOL was assessed in patients who underwent allogeneic stem cell transplantation (allo-SCT) at the University Hospital Centre Zagreb and were alive and in complete remission for more than one year after allo-SCT.

**Results** The study included 58 patients, 38 patients with cGVHD and 20 controls, patients without cGVHD. Patients with cGVHD scored according to the NIH criteria had significantly lower scores of global health status and lower QOL on all SF-36 subscales and most of QLQ C30 functional subscales \((P < 0.050\) for all comparisons). Furthermore, patients with active cGVHD had significantly lower QOL scores than patients with inactive cGVHD, and this difference was most evident in physical functioning subscale of SF-36 \((P = 0.0007)\) and social functioning subscale of QLQ C30 \((P = 0.009)\).

**Conclusion** cGVHD scored according to the NIH criteria is correlated with patient-reported QOL, particularly in the physical domains as detected by SF-36. QLQ C30 questionnaire adds more information on social functioning and should be used as a valuable tool in the evaluation of social domains in cGVHD patients.
Although it is potentially lifesaving for a variety of hematological malignant and non-malignant disorders, allogeneic stem cell transplantation (allo-SCT) carries a significant risk of acute and late post-transplant complications. Improvements in transplantation techniques and supportive care have resulted in a reduction of early transplant-related mortality (1,2). However, the burden of late complications remains high, and two thirds of long-term allo-SCT survivors experience at least one chronic health condition (3). These complications occur due to treatment exposures before and during allo-SCT, cause substantial mortality, and severely impair patients’ functional status and quality of life (QOL). This is why today the aim of the treatment is not just to cure the primary hematological disease, but to facilitate the recovery of the physical and emotional functioning and improve QOL and social reintegration in family and work environment.

Health-related QOL is now considered to be one of the relevant treatment outcomes because it provides a broader understanding of the patient’s status beyond simple disease-free survival. It is a multi-dimensional construct comprised of several related domains including physical, emotional, social, and role functioning, as well as a person’s overall evaluation of his or her well-being and ability to function (4,5). Better understanding of QOL in long-term survivors is necessary to provide adapted pre-transplant counseling and recommendations for post-transplant follow-up.

With a cumulative incidence of 40%-70% and significant mortality, chronic GVHD (cGVHD) represents the most important late complication following allo-SCT (6,7). Moreover, it seems that the incidence of cGVHD in the recent years has been increasing, probably due to the fact that much older patients undergo allo-SCT, as well as due to the increased use of peripheral blood stem cell grafts and matched unrelated donors, all known risk factors for cGVHD (8). In a series of publications originating from 2005 National Institutes of Health (NIH) Consensus Conference, investigators proposed means to standardize diagnosis, scoring, histopathology, biomarkers, response assessment, and research in cGVHD (9-14). These criteria were developed to advance clinical trials and consequently improve the management of cGVHD and long-term survivorship after allo-SCT.

As one of the important treatment outcomes, QOL is increasingly being subjected to the same degree of rigorous study as other significant allo-SCT outcomes. Most of the studies so far have reported a negative, significant association between cGVHD and QOL after allo-SCT (15-20). However, some of the studies have found no association (21-25), and this relationship still needs to be elucidated. The awareness of the relationship between QOL and cGVHD is necessary to further facilitate the prevention and treatment of cGVHD.

The aim of this study was to examine the effect of cGVHD on QOL in our cohort of long-term allo-SCT survivors with the use of two standard QOL questionnaires; The Short Form (36-item) Health Survey (SF-36) and The EORTC Quality of Life Questionnaire (QLQ C30). Furthermore, we assessed QOL according to cGVHD severity and activity defined by the NIH consensus criteria.

PATIENTS AND METHODS

Study design

This cross-sectional study was part of a larger project titled “Clinical and Biological Factors Determining Severity and Activity of Chronic GVHD after Allogeneic Hematopoietic Stem Cell Transplantation” funded by the Unity Through Knowledge Fund. This project was conducted at the University Hospital Centre Zagreb, received Ethical approval from the same institution as well as from School of Medicine, University of Zagreb. The project included all patients referred to hematologist for the evaluation of cGVHD independently of age or underlying diagnosis. Between July 2013 and October 2015, total of 76 patients, 47 cGVHD patients and 29 controls were included in the project.

The inclusion criteria for this study were patients in the project who were alive and in complete remission for more than one year after allo-SCT. Children were excluded from this study. From 60 patients who met the criteria for the study, two refused to participate, one due to cGVHD-related sight problems and another due to personal reasons. Fifty-eight patients who accepted to participate signed an informed consent for the study.

Chronic GVHD evaluation

cGVHD was evaluated and scored according to the NIH consensus criteria (14). No-cGVHD cohort of patients were patients who had never had signs of cGVHD, irrespective of their acute GVHD status. If they had standard or late-acute cGVHD, it had to be resolved and they did not receive any immunosuppression at the time of
For patients with established cGVHD diagnosis, additional data regarding the severity and activity of disease were collected. Disease severity was defined according to the global NIH scoring: mild cGVHD involved only 1 or 2 organs (except lungs, maximum score 1 in all affected organs). Moderate cGVHD involved at least 1 organ with clinically significant but not major disability (maximum score 2) or 3 or more organs with no clinically significant functional impairment (maximum score 1 in all affected organs). Lung score 1 was classified as moderate. Severe cGVHD indicated major impairment caused by cGVHD (score 3 in any organ). Lung scores of 2 or 3 were classified as severe. Organs scored included the skin, eyes, mouth, gastrointestinal tract, liver, lungs, and joint/fascia. The genital area was scored only in women (14). In order to establish disease activity we noted a) Clinicians’ impression of activity previously defined by Grkovic et al (26) as inactive off systemic therapy or topical immunosuppression, inactive on systemic therapy or topical immunosuppression, active irrespective of the level of current therapy, or highly active irrespective of the level of current therapy, and b) intensity of immunosuppression at the time of evaluation defined as: none, mild = single agent prednisone ≤0.5 mg/kg/d; moderate = prednisone ≥0.5 mg/kg/d and/or any single agent/modality; high = 2 or more agents/modalities ± prednisone ≥0.5 mg/kg/d (27).

Quality of life instruments

Patients received two questionnaires at the time of project enrollment: SF-36 and EORTC QLQ-C30. SF-36 is a 36-item self-report questionnaire that assesses patient-reported health and functioning. The instrument examines the following domains of QOL: physical functioning, role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional well-being, social functioning, pain, and general health (28,29). SF-36 was translated and validated in Croatian at the School of Public Health “Andrija Štampar” for the purposes of the health care analysis project and later used in many different studies in Croatia (30-32).

The EORTC QLQ-C30 (33) is a cross-culturally validated questionnaire of 30 questions, which make 5 multi-item functional scales (physical, role, emotional, cognitive, and social functioning), and a combined global health status/QOL scale. Higher scores on these scales indicate better functioning (33). Three symptom scales measure fatigue, pain, nausea, and vomiting, while 6 single items assess symptoms commonly reported by cancer patients (dyspnea, sleep disturbances, appetite loss, diarrhea, constipation, and financial impact). Higher scores on the symptom scales and single items represent greater higher impairments. QLQ-C30 version translated and validated in Croatian was obtained for this research from the EORTC QOL group headquartered in Belgium.

Statistical methods

All analyses were performed using the R package (34). Data are presented as median and range. Comparisons of global QOL, physical, role, emotional, social functioning, and symptom scales between patients with and without cGVHD and between patients with moderate and severe cGVHD, were evaluated by a non-parametric Mann-Whitney U test. Comparisons between groups with regard to activity of cGVHD and level of immunosuppression were done with Kruskal-Wallis test. P value ≤0.050 was considered significant.

RESULTS

Study population characteristics

Patients’ and graft characteristics are presented in Table 1. The study included 30 male and 28 female patients with a median age of 43 years (range 18-71). Most of the patients (69%) underwent transplantation due to myeloid malignancies, 22% due to lymphoid malignancies, and 9% due to aplastic anemia. The majority of patients (60%) underwent transplantation after myeloablative conditioning, while 40% received reduced-intensity conditioning prior to allo-SCT. In 62% of patients the donor was related to the patients and in 38% of patients the donor was unrelated. Finally, the majority of the patients received peripheral blood stem cells (57%), while the rest (43%) received the bone marrow. The median follow-up after allo-SCT was 659 days (range 361-7853). Baseline clinical characteristics were similar in patients with and without cGVHD (Table 1).

Chronic GVHD characteristics

cGVHD characteristics are shown in Table 2. 20 patients did not meet the NIH criteria for cGVHD diagnosis. In the no cGVHD group, 60% of patients previously had had acute GVHD but it completely resolved at the time of evaluation and they did not receive any immunosuppressive therapy.

cGVHD was diagnosed in 38 patients; mild in 1, moderate in 17, and severe in 20 patients, at a median of 298 days
Perić et al: QOL in cGVHD patients

after HSCT (range 103-3886). 79% of cGVHD patients previously had acute GVHD. cGVHD onset was quiescent in the majority of patients (47%), progressive in 32%, and it occurred de novo in 21% of the patients. At the time of the evaluation, cGVHD was classified as classic in 92% of the patients, and in 8% of the patients it overlapped with acute GVHD. The median number of cGVHD organs involved was 2 (range 1-6), and patients received a median of 2 (range 1-4) previous lines of immunosuppressive treatment. According to the clinical impression, 53% of patients had active or even highly active cGVHD irrespective of the immunosuppressive treatment, while 34% had inactive cGVHD and were off immunosuppressive therapy. The remaining 13% of the patients had inactive cGVHD but still received immunosuppressive treatment. The majority of patients (53%) received no immunosuppressive treatment at the time of enrolment, 29% were treated with moderate immunosuppression, while 18% of patients received high-dose immunosuppressive therapy.

Quality of life

In the analysis of QOL of all patients, we found that female patients, patients older than 50 years, and patients who fulfilled the questionnaires less than two years after allo-SCT had lower QOL scores than men, younger patients, or patients with longer follow up, although this difference did not reach statistical significance (data not shown). On average, cGVHD patients had lower QOL scores than the general population. The median number of cGVHD organs involved was 2 (range 1-6), and patients received a median of 2 (range 1-4) previous lines of immunosuppressive treatment. According to the clinical impression, 53% of patients had active or even highly active cGVHD irrespective of the immunosuppressive treatment, while 34% had inactive cGVHD and were off immunosuppressive therapy. The remaining 13% of the patients had inactive cGVHD but still received immunosuppressive treatment. The majority of patients (53%) received no immunosuppressive treatment at the time of enrolment, 29% were treated with moderate immunosuppression, while 18% of patients received high-dose immunosuppressive therapy.

| Characteristic                                      | N (%)          | P (Mann-Whitney) |
|----------------------------------------------------|----------------|-----------------|
| Patient age median (range)                         |                | 0.312           |
| Sex                                                |                |                 |
| male                                               | 19 (50)        | 30 (52)         |
| female                                             | 19 (50)        | 28 (48)         |
| Diagnosis                                          |                |                 |
| myeloid malignancies                               | 26 (68)        | 40 (69)         |
| lymphoid malignancies                              | 8 (21)         | 13 (22)         |
| aplastic anemia                                    | 4 (11)         | 5 (9)           |
| Stem cell source                                   |                | 0.832           |
| bone marrow                                        | 16 (42)        | 25 (43)         |
| peripheral blood stem cells                        | 22 (58)        | 33 (57)         |
| Donor type                                         |                | 1.00            |
| matched related donor                              | 25 (66)        | 36 (62)         |
| matched unrelated donor                            | 13 (44)        | 22 (38)         |
| Conditioning regimen                                |                | 0.583           |
| myeloablative                                      | 23 (60)        | 35 (60)         |
| reduced-intensity                                  | 15 (40)        | 23 (40)         |
| Days from transplant to enrolment, median (range)  | 606 (367-7853) | 0.472           |

*QOL – quality of life.

**TABLE 2. Characteristics of chronic graft-vs-host disease (cGVHD) patients**

| Characteristic                                      | N (%)          | P (Mann-Whitney) |
|----------------------------------------------------|----------------|-----------------|
| cGVHD                                              |                |                 |
| mild                                               | 1 (2)          |                 |
| moderate                                           | 17 (45)        |                 |
| severe                                             | 20 (53)        |                 |
| days after transplantation                          | 298 (103-3886) |                 |
| cGVHD onset                                        |                |                 |
| de novo                                            | 8 (21)         |                 |
| progressive                                        | 12 (32)        |                 |
| quiescent                                          | 18 (47)        |                 |
| classification time of evaluation                  |                |                 |
| classic                                            | 35 (92)        |                 |
| overlap                                            | 3 (8)          |                 |
| organs involved                                    |                |                 |
| median (range)                                     | 2 (1-6)        |                 |
| lines of immunosuppression                          |                |                 |
| median (range)                                     | 2 (1-4)        |                 |
| Clinician’s impression of cGVHD activity           |                |                 |
| inactive systemic or topical immunosuppression      | 13 (34)        |                 |
| inactive systemic or topical immunosuppression      | 5 (13)         |                 |
| active irrespective of immunosuppression            | 17 (45)        |                 |
| highly active irrespective of immunosuppression     | 3 (8)          |                 |
| Intensity of immunosuppression at time of evaluation|                |                 |
| none                                               | 20 (53)        |                 |
| moderate                                           | 11 (29)        |                 |
| high                                               | 7 (18)         |                 |

**TABLE 1. Demographic characteristics of the study population, N (%)**
the other hand, compared to patients without cGVHD, patients with cGVHD had significantly lower mean scores on all QOL subscales of the SF 36 questionnaire. Namely, cGVHD patients had significantly lower scores on physical functioning subscale, more role limitations due to physical and emotional functioning, less energy, worse emotional well-being and social functioning, more pain, and worse general health ($P < 0.050$ for all comparisons) (Table 3). cGVHD patients also had significantly lower QOL scores on QLQ C30 global health status and on most functional subscales (physical, role, emotional, and social) ($P < 0.050$ for all subscales). The difference was not significant only for cognitive functioning (Table 4). Moreover, on QLQ C30 symptom scales, cGVHD patients reported significantly more pain, dyspnea, and sleeping disorders ($P = 0.010$, $P = 0.043$, and $P = 0.043$, respectively) (Table 4). There was no difference in the scores for other symptoms: fatigue, nausea and vomiting, constipation, diarrhea, appetite loss, and financial difficulties. When we evaluated the severity of the cGVHD, patients with severe cGVHD had lower QOL scores than patients with mild/moderate cGVHD on both SF-36 (Figure 1) and QLQ C30 questionnaires (Figure 2). This difference was greatest in physical functioning and role limitations due to physical health on SF-36, as well as in global status and social functioning scores on QLQ C30, but it did not reach statistical difference. According to clinician’s impression, we further divided the patients with cGVHD into those with active disease (active or highly active irrespectively of immunosuppressive treatment) and inactive (irrespectively of immunosuppressive therapy). Patients with active cGVHD had consistently lower QOL SF-36 scores, ie, significantly lower physical functioning, role limitations due to physical health, and social functioning, as well as less energy/more fatigue ($P = 0.0007$, $P = 0.026$, $P = 0.007$, $P = 0.025$, $P = 0.004$, $P = 0.005$, $P = 0.017$, $P = 0.084$, $P = 0.001$, $P = 0.063$, $P = 0.312$, $P = 0.010$, $P = 0.043$, $P = 0.043$, $P = 0.190$, $P = 0.356$, $P = 0.139$).

**Table 3.** Mean scores in the Short Form (36) Health Survey (SF-36) questionnaire subscales in patients with and without chronic graft-vs-host disease (cGVHD)

| SF-36 mean (standard deviation) | Patients without cGVHD (n = 20) | Patients with cGVHD (n = 38) | $P$ (Mann-Whitney) |
|----------------------------------|----------------------------------|-------------------------------|--------------------|
| Physical functioning             | 72.86 (24.06)                   | 53.84 (26.27)                | 0.007              |
| Role limitations due to physical health | 63.10 (42.29)                   | 34.46 (40.97)                | 0.025              |
| Role limitations due to emotional problems | 84.13 (32.69)                   | 45.94 (44.69)                | 0.004              |
| Energy/Fatigue                  | 66.19 (18.30)                   | 49.39 (19.04)                | 0.005              |
| Emotional well-being            | 73.86 (13.71)                   | 61.00 (19.23)                | 0.017              |
| Social functioning              | 82.14 (19.19)                   | 56.76 (26.29)                | 0.0004             |
| Pain                            | 78.93 (22.84)                   | 59.53 (28.30)                | 0.008              |
| General health                  | 62.20 (21.42)                   | 43.26 (19.62)                | 0.018              |

**Table 4.** Mean scores in The EORTC Quality of Life Questionnaire C30 (QLQ C30) questionnaire subscales in patients with and without chronic graft-vs-host disease (cGVHD)

| QLQ C30 mean (standard deviation) | Patients without cGVHD (n = 20) | Patients with cGVHD (n = 38) | $P$ (Mann-Whitney) |
|----------------------------------|----------------------------------|-------------------------------|--------------------|
| Global health status             | 75.00 (21.25)                   | 52.70 (25.16)                | 0.001              |
| Functional scales                |                                  |                               |                    |
| physical functioning             | 79.05 (20.36)                   | 64.68 (24.09)                | 0.022              |
| role functioning                 | 80.16 (29.16)                   | 54.50 (33.94)                | 0.005              |
| emotional functioning            | 78.32 (21.79)                   | 62.16 (25.05)                | 0.017              |
| cognitive functioning            | 85.71 (12.12)                   | 70.72 (28.17)                | 0.084              |
| social functioning               | 79.37 (18.93)                   | 49.55 (32.98)                | 0.001              |
| Symptom scale                    |                                  |                               |                    |
| fatigue                          | 28.78 (20.53)                   | 42.26 (26.92)                | 0.063              |
| nausea and vomiting              | 4.76 (10.73)                    | 10.36 (19.39)                | 0.312              |
| pain                             | 17.46 (25.54)                   | 42.72 (35.69)                | 0.010              |
| dyspnea                          | 20.63 (24.67)                   | 36.94 (28.09)                | 0.043              |
| insomnia                         | 22.22 (26.53)                   | 38.74 (27.79)                | 0.043              |
| appetite loss                    | 12.70 (24.67)                   | 26.13 (34.37)                | 0.190              |
| constipation                     | 4.76 (11.95)                    | 13.51 (24.16)                | 0.356              |
| financial disturbances           | 30.16 (31.46)                   | 46.85 (39.64)                | 0.139              |
Patients with active cGVHD also had significantly lower QLQ C30 scores, ie, worse physical and role functioning, as well as global health, and social functioning ($P=0.015$, $P=0.011$, $P=0.029$, and $P=0.009$, respectively) (Table 5). Finally we examined QOL in patients with cGVHD according to the level of immunosuppressive treatment at the time of evaluation. Patients with high and moderate intensity of immunosuppression had significantly lower scores on physical functioning subscale ($P=0.044$) and role limitations due to physical health ($P=0.031$) of SF-36 (Table 5) and on general health subscale ($P=0.039$), as well as more pain on the symptom scales ($P=0.033$) of QLQ C30 (Table 6).

**DISCUSSION**

In this study we investigated the ability of standard QOL questionnaires, SF-36 and QLQ C30, to evaluate QOL in patients with cGVHD graded according to NIH consensus criteria. Previous reports have identified cGVHD as the most important predictor of adverse long-term late effects and poor overall health after allo-SCT (3, 35, 36). Moreover, previous studies have mostly shown the adverse impact of cGVHD on health-related QOL (15-20). The limitations in assessing the results of these reports are related to their heterogeneous nature. Also, most of these studies evaluated QOL with regard to cGVHD without reviewing its severity or by grading the severity according to the old scoring system developed in the 1980s (37). Only one study examined the relationship between cGVHD severity defined by the new NIH Consensus criteria and QOL, and this was done with two standard QOL questionnaires – SF-36 and Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT). This study found cGVHD severity to be independently associated with QOL in both questionnaires, adjusted for age (38).
In our study, older age, female sex, and short follow-up were not found to be predictive factors of worse QOL, as it was shown before (18,39,40). However, we confirmed that patients with cGVHD reported significantly lower QOL than control patients without cGVHD on all functional scales and general well-being evaluated by SF-36. Moreover, QOL of patients without cGVHD was comparable to normative data of the Croatian population measured with SF-36 (30). To the best of our knowledge, this is the first report to evaluate QOL with EORTC QOL C30 questionnaire in patients with cGVHD defined by the NIH Consensus criteria. Compared with previous findings on QOL C30 in allo-SCT, which show improvement of QOL scores over time (41), our patients without cGVHD had similar mean QOL scores as patients more than 3 years after allo-SCT, while cGVHD patients had scores comparable to QOL of patients at discharge from the hospital after allo-SCT. In our study population the differences between cGVHD patients and no-cGVHD controls were most evident in global health status, and physical and social well-being. These results indicate that C30 adds more information on social well-being of cGVHD patients and should be used as a valuable instrument of evaluation in the social domains of QOL.

When we compared patients with moderate cGVHD to patients with severe cGVHD, patients with moderate cGVHD had higher QOL subscale scores, but the difference was not significant, presumably due to the small number of patients. For the same reason, we could not compare the difference in QOL between patients with mild and moderate cGVHD, as we had only one patient with mild cGVHD. This is probably due to the referral pattern of these patients to our institution and some of the mild cGVHD have probably stayed undetected. Additionally, we evaluated QOL in cGVHD patients according to the cGVHD activity and intensity of immunosuppressive treatment. As patients with inactive cGVHD and patients without immunosuppressive therapy had better QOL scores, our results confirmed that the resolution of cGVHD and discontinuation of immunosuppressive treatment reduced QOL impairment in cGVHD patients.

Our study has a number of limitations. We used a group of patients from a single institution, and patients were included in the study at different time points after allo-SCT using heterogeneous transplant regimens. However, the patients were also part of a prospective observational study and therefore they had to meet the same inclusion criteria and were evaluated in a homogenous manner. Nevertheless, our ability to draw conclusions in a heterogeneous patient group supports the use of both SF-36 and C30 as valuable tools in the evaluation of the effect of GVHD on QOL in different clinical settings.

### TABLE 6. Mean scores in the EORTC Quality of Life Questionnaire C30 (QLQ C30) questionnaire subscales according to chronic graft-vs-host disease (cGVHD) activity and intensity of immunosuppression

| QLQ C30 mean (standard deviation) | Patients with inactive cGVHD (n = 18) | Patients with active or highly active cGVHD (n = 20) | P (Mann-Whitney test) | Intensity of immunosuppression (n = 20) | P (Kruskal-Wallis test) |
|----------------------------------|---------------------------------------|-----------------------------------------------|------------------------|----------------------------------------|------------------------|
| Global health status             | 63.42 (22.89)                         | 44.58 (24.52)                                 | 0.015                  | 59.12 (26.99)                          | 55.30 (20.16)          | 33.33 (15.96)          | 0.039 |
| Functional scales                |                                       |                                               |                        |                                        |                        |                        |      |
| physical functioning             | 75.0 (20.90)                          | 56.50 (23.73)                                 | 0.011                  | 72.06 (21.89)                          | 63.03 (17.98)          | 49.52 (31.24)          | 0.096 |
| role functioning                 | 66.52 (32.28)                         | 44.17 (32.57)                                 | 0.029                  | 61.91 (33.81)                          | 59.09 (33.64)          | 33.33 (28.87)          | 0.142 |
| emotional functioning            | 66.20 (28.51)                         | 60.00 (22.06)                                 | 0.427                  | 64.29 (23.88)                          | 62.12 (33.41)          | 55.95 (14.99)          | 0.583 |
| cognitive functioning            | 72.22 (24.15)                         | 70.00 (27.36)                                 | 0.726                  | 73.02 (26.60)                          | 71.21 (31.70)          | 64.29 (26.22)          | 0.668 |
| social functioning               | 65.74 (24.41)                         | 37.50 (31.93)                                 | 0.009                  | 61.91 (31.69)                          | 45.46 (28.96)          | 28.57 (34.31)          | 0.070 |
| Symptom scale                    |                                       |                                               |                        |                                        |                        |                        |      |
| fatigue                          | 33.26 (20.16)                         | 49.92 (29.59)                                 | 0.057                  | 40.65 (23.39)                          | 36.30 (27.69)          | 58.67 (31.18)          | 0.169 |
| nausea and vomiting              | 3.70 (7.13)                           | 15.83 (24.47)                                 | 0.121                  | 9.52 (22.71)                           | 6.06 (11.24)           | 19.05 (14.99)          | 0.152 |
| pain                             | 35.19 (31.77)                         | 47.50 (39.09)                                 | 0.349                  | 38.09 (35.80)                          | 30.30 (31.88)          | 73.81 (21.21)          | 0.033 |
| dyspnea                          | 31.48 (24.18)                         | 40.00 (31.72)                                 | 0.474                  | 39.68 (29.09)                          | 27.27 (25.03)          | 42.86 (31.71)          | 0.492 |
| insomnia                         | 38.89 (26.19)                         | 40.00 (29.81)                                 | 0.953                  | 42.86 (30.08)                          | 27.27 (20.10)          | 52.38 (26.23)          | 0.133 |
| appetite loss                    | 16.67 (30.78)                         | 33.33 (35.87)                                 | 0.147                  | 25.39 (36.37)                          | 21.21 (26.97)          | 33.33 (38.49)          | 0.814 |
| constipation                     | 18.52 (28.52)                         | 8.33 (18.33)                                  | 0.396                  | 14.29 (24.88)                          | 9.09 (21.56)           | 14.29 (9.91)           | 0.882 |
| diarrhea                         | 5.56 (12.78)                          | 10.53 (24.97)                                 | 0.785                  | 7.94 (14.55)                           | 3.03 (10.05)           | 16.67 (40.83)          | 0.805 |
| financial disturbances           | 46.29 (41.44)                         | 46.67 (38.08)                                 | 0.971                  | 34.92 (37.23)                          | 57.58 (36.79)          | 57.14 (46.0)           | 0.234 |
Today, there is a widespread interest in possible interventions to improve QOL in long-term allo-SCT survivors. Behavioral interventions, such as supervised exercise during hospitalization for allo-SCT, have been shown to result in better long-term physical well-being, decreased fatigue, and emotional distraction (42-44). Furthermore, psychosocial interventions, such as stress management and coping skills training reduced pain in allo-SCT survivors (45,46). Finally, a dedicated GVHD clinic with an active involvement of specialists interested in GVHD can also improve QOL of patients with cGVHD (47).

In conclusion, we confirmed QOL as a valid measure of cGVHD defined and staged by NIH consensus criteria. The results suggest that SF-36 is a useful questionnaire in the evaluation of cGVHD effect on QOL, particularly in the physical domains, while QLQC30 provides additional value, especially in social domains. Future studies are needed to continue longitudinal QOL assessment by the same means in order to improve the outcomes of cGVH patients.

Acknowledgment The opinions expressed here are those of the authors and do not represent the official position of the NIH or the U.S. Government.

Funding This work was funded by the Unity Through Knowledge Fund project entitled “Clinical And Biological Factors Determining Severity And Activity of Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation”. It was also partly supported by the Center for Cancer Research, the intramural program of the National Cancer Institute, Stem Cell Transplantation” . It was also partly supported by the Center for activity of Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Blood. 2010;116:3129-39, quiz 377. Published online 07 27, 2010. Medline:20656930 doi:10.1182/ blood-2009-06-229369

4 Halyard MT, Ferrans CE. Quality-of-Life assessment for routine oncology clinical practice. J Support Oncol. 2008;6:221-9, 33. Medline:18551858

5 Pidala J, Anasetti C, Jim H. Quality of life after allogeneic hematopoietic cell transplantation. Blood. 2009;114:7-19. Medline:19336756 doi:10.1182/blood-2008-10-182592

6 Duell T, van Lint MT, Ljungman P, Tichelli A, Socie G, Apperley, et al. Health and functional status of long-term survivors of bone marrow transplantation. EBMT Working Party on Late Effects and EULIP Study Group on Late Effects. European Group for Blood and Marrow Transplantation. Ann Intern Med. 1997;126:184-92. Medline:9027268 doi:10.1200/0000-4819-126-3-19970201-00002

7 Lee SJ, Flowers ME. Recognizing and managing chronic graft-versus-host disease. Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2008:134-41. medline:2009-06-229369

8 Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015;21:666-74. Medline:25445023 doi:10.1016/j.bbtm.2014.10.021

9 Couriel D, Carpenter PA, Cutler C, Bolanos-Meade J, Treister NS, Gea-Banacloche J, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2006;12:375-96. Medline:16545722 doi:10.1016/j.bbtm.2006.02.003

10 Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobson D, Cowen EW, et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant. 2006;12:252-66. Medline:16503494 doi:10.1016/j.bbtm.2006.01.008

11 Schultz KR, Miklos DB, Fowler D, Cooke K, Shizuru J, Zorn E, et al. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol Blood Marrow Transplant. 2006;12:126-
12 Shulman HM, Kleiner D, Lee SJ, Morton T, Pavletic SZ, Farmer E, et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant. 2006;12:31-47. Medline:16399567 doi:10.1016/j.bbmt.2005.10.023

13 Martin PJ, Weisdorf D, Przepiorka D, Hirschfeld S, Farrell A, Rizzo JD, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant. 2006;12:491-505. Medline:16635784 doi:10.1016/j.bbmt.2006.03.004

14 Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host-disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945-56. Medline:16338616 doi:10.1016/j.bbmt.2005.09.004

15 Lee SJ, Kim HT, Ho VT, Cutler C, Alyea EP, Soiffer RJ, et al. Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant. 2006;38:305-10. Medline:16819438 doi:10.1038/sj.bmt.1705434

16 Syrjala KL, Chapko MK, Vitaliano PP, Cummings C, Sullivan KM. Recovery after allogeneic marrow transplantation: prospective study of predictors of long-term physical and psychosocial functioning. Bone Marrow Transplant. 1993;11:319-27. Medline:8485479

17 Kiss TL, Abdolell M, Altman MA, Antin JH, Gingrich R, et al. Quality of life following bone marrow transplantation: findings from a multicentre study. Br J Cancer. 1995;71:1322-9. Medline:7779732 doi:10.1038/bjc.1995.257

18 Chiodi S, Spinelli S, Ravera G, Petti AR, Van Lint mt, Lamparelli t, Kiss tL, Abdolell m, Jamal N, minden mD, Lipton Jh, Gingrich R, et al. Quality of life following bone marrow transplantation: findings from a multicentre study. Br J Cancer. 1995;71:1322-9. Medline:7779732 doi:10.1038/bjc.1995.257

19 Fraser CJ, Bhatia S, Ness K, Carter A, Francisco L, Arora M, et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood. 2006;108:2867-73. Published online 06 22, 2006. Medline:16788100 doi:10.1182/blood-2006-02-003954

20 Worel N, Biener D, Kalhs P, Mitterbauer M, Kefl F, Schubenburg A, et al. Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation. Bone Marrow Transplant. 2002;30:619-26. Medline:12407437 doi:10.1038/sj.bmt.1703677

21 Hjermstad MJ, Evensen SA, Kvaloy SO, Fayers PM, Kaasa S. Health-related quality of life 1 year after allogeneic or autologous stem-cell transplantation: a prospective study. J Clin Oncol. 1999;17:706-18. Medline:10080617

22 Andrykowski MA, Greiner CB, Altman MA, Burish TG, Antin JH, Gingrich R, et al. Physical and psychosocial functioning of 117 survivors of bone marrow transplantation. Bone Marrow Transplant. 1996;17:1133-42. Medline:8807126

23 Prieto JM, Saez R, Carreras E, Atala J, Sierra J, Rovira M, et al. Long-term and psychosocial functioning of 117 survivors of bone marrow transplantation: comparison with a matched group receiving maintenance chemotherapy. Bone Marrow Transplant. 1996;17:249-58. Medline:8640175

24 Molassiotis A, van den Akker OB, Milligan DW, Goldman JM, Boughton JJ, Holmes JA, et al. Quality of life in long-term survivors of marrow transplantation: comparison with a matched group receiving maintenance chemotherapy. Bone Marrow Transplant. 1996;17:249-58. Medline:8640175

25 Syrjala KL, Langer SL, Abrams JR, Storer B, Sanders JE, Flowers ME, et al. Recovery and long-term function after hematopoietic stem cell transplantation for leukemia or lymphoma. JAMA. 2004;291:2335-43. Medline:15150205 doi:10.1001/jama.291.19.2335

26 Grkovic L, Baird K, Steinberg SM, Williams KM, Punic D, Cowen EW, et al. Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host-disease activity and NIH global severity. Leukemia. 2012;26:633-43. Medline:22005783 doi:10.1038/leu.2011.254

27 Mitchell SA, Leidy NK, Mooney KH, Dudley WN, Beck SL, LaStayo PC, et al. Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD). Bone Marrow Transplant. 2010;45:762-9. Medline:19784078 doi:10.1038/bmt.2009.238

28 McHorney CA, Ware JE, Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31:247-63. Medline:8450681 doi:10.1097/00005650-199303000-00006

29 Ware JE, Kosinski M. Interpreting SF-36 summary health measures: a response. Qual Life Res. 2001;10:405-13, discussion 15-20. Medline:11763203 doi:10.1023/A:1012588218728

30 Juresa V, Ivankovic D, Vuletic G, Babic-Banaszak A, Srcek i, Mastilica M, et al. The Croatian Health Survey–SF-36: i. General quality of life. Lijec Vjesn. 2002;124 Suppl 2:64-70. Medline:19702134

31 Maslic Sersic D, Vuletic G. Psychometric evaluation and establishing norms of Croatian SF-36 health survey: framework for subjective health research. Croat Med J. 2006;47:95-102. Medline:16489702
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-76. Medline:8433390 doi:10.1093/jnci/85.5.365

Team RDCR. A language and environment for statistical computing. R Foundation for Statistical Computing. 2006;Vienna, Austria. Available from: http://www.R-project.org. Accessed: February 72, 2016.

Baker KS, Gurney JG, Ness KK, Bhatia R, Forman SJ, Francisco L, et al. Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study. Blood. 2004;104:1898-906. Medline:15172972 doi:10.1182/blood-2004-03-1010

Savani BN, Koklanaris EK, Le Q, Shenoy A, Goodman S, Barrett AJ. Prolonged chronic graft-versus-host disease is a risk factor for thyroid failure in long-term survivors after matched sibling donor stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2009;15:377-81. Medline:19203730 doi:10.1016/j.bmt.2008.11.032

Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204-17. Medline:6996481 doi:10.1016/0002-9343(80)90380-0

Pidala J, Kurland B, Chai X, Majhail N, Weisdorf DJ, Pavletic S, et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood. 2011;117:4651-7. Medline:21355084 doi:10.1182/blood-2010-11-319509

Andrewskovs MA, Bruehl S, Brady MJ, Henslee-Downey PJ. Physical and psychosocial status of adults one-year after bone marrow transplantation: a prospective study. Bone Marrow Transplant. 1995;15:837-44. Published online 06 01, 1995. Medline:7581078

Baker F, Wingard JR, Curbow B, Zabora J, Jodrey D, Fogarty L, et al. Quality of life of bone marrow transplant long-term survivors. Bone Marrow Transplant. 1994;13:589-96. Medline:8054912

Gruinke N, Albani C, Bailer H. Quality of life in patients before and after haematopoietic stem cell transplantation measured with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire QLQ-C30. Bone Marrow Transplant. 2012;47:473-82. Medline:21602898 doi:10.1038/bmt.2011.107

DeFor TE, Burns LJ, Gold EM, Weisdorf DJ. A randomized trial of the effect of a walking regimen on the functional status of 100 adult allogeneic donor hematopoietic cell transplant patients. Biol Blood Marrow Transplant. 2007;13:948-55. Medline:17640599 doi:10.1016/j.bbmt.2007.04.008

Carlson LE, Smith D, Russell J, Fibich C, Whittaker T. Individualized exercise program for the treatment of severe fatigue in patients after allogeneic hematopoietic stem-cell transplant: a pilot study. Bone Marrow Transplant. 2006;37:945-54. Medline:16565742 doi:10.1038/sj.bmt.1705343

Wilson RW, Jacobsen PB, Fields KK. Pilot study of a home-based aerobic exercise program for sedentary cancer survivors treated with hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005;35:721-7. Medline:15696182 doi:10.1038/sj.bmt.1704815

Syrjala KL, Cummings C, Donaldson GW. Hypnosis or cognitive behavioral training for the reduction of pain and nausea during cancer treatment: a controlled clinical trial. Pain. 1992;48:137-46. Medline:1350338 doi:10.1016/0304-3959(92)90049-H

Syrjala KL, Donaldson GW, Davis MW, Kippes ME, Carr JE. Relaxation and imagery and cognitive-behavioral training reduce pain during cancer treatment: a controlled clinical trial. Pain. 1995;63:189-98. Medline:8628584 doi:10.1016/0304-3959(95)00039-U

Dignan FL, Mamwani R, Potter MN, Ethell ME, Leonard H, Brennan J, et al. A dedicated GVHD clinic may improve the quality of life for allogeneic stem cell transplant survivors. Clin Transplant. 2013;27:E1-2. Medline:23215823 doi:10.1111/ctr.12051